Yıl: 2023 Cilt: 53 Sayı: 6 Sayfa Aralığı: 1697 - 1703 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5738 İndeks Tarihi: 17-01-2024

Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome

Öz:
Background/aim: This study was designed to evaluate the relationship of two new biomarkers [tribbles homolog 3 (TRB3) and sestrin 2 levels], which were previously associated with obesity, with metabolic parameters in obese and nonobese women with polycystic ovary syndrome (PCOS). Materials and methods: This cross-sectional case control study was conducted between September 2017 and August 2019 in the gynecology department of a tertiary referral hospital. The values of the plasma sestrin 2, TRB3, insulin, fasting plasma glucose, lipid profile, and homeostasis model assessment of insulin resistance (HOMA-IR) were compared in 90 obese women with PCOS (BMI > 30), 90 women with nonobese PCOS (BMI < 30), and 90 control patients (BMI < 30). Results: The mean age of the study group consisting of all PCOS patients (26.11 ± 4.64 years) and the mean age of the control group (26.3 ± 4.4 years) were statistically similar (p = 0.239). The serum sestrin 2 values of the obese PCOS group were found to be statistically significantly lower than the control and non-obese PCOS groups (p = 0.001, p = 0.0001), while the sestrin 2 values of the nonobese PCOS group were found to be statistically significantly lower than the control group (p = 0.0001). The TRB3 values of the control group were found to be statistically significantly lower than the obese and nonobese PCOS groups (p = 0.0001), while the TRB3 values of the nonobese PCOS group were found to be statistically significantly lower than the obese PCOS group (p = 0.0001). A negative correlation was observed between the sestrin 2 level and BMI (r = −0.272 p = 0.0001), insulin (r = −0.261 p = 0.0001), and HOMA-IR levels (r = −0.250 p = 0.0001). A positive correlation was observed between the TRB3 values and TG (r = 0.248 p = 0.0001), and LDL-C values (r = 0.235 p = 0.0001). Conclusion: According to the findings in this study, low sestrin 2 and high TRB3 levels may be related to impaired metabolic status in the obese PCOS group. Thus, it may be promising for the development of treatment of PCOS and associated metabolic disorder in the future.
Anahtar Kelime: Insulin resistance obesity polycystic ovary syndrome sestrin 2 tribbles homolog 3

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. Journal of Endocrinological Investigation 2017; 40 (1): 1-8. https://doi. org/10.1007/s40618-016-0523-8
  • 2. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility 2018; 110 (3): 364-379. https://doi.org/10.1016/j. fertnstert.2018.05.004
  • 3. Mohammad MB, Seghinsara AM. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pacific Journal of Cancer Prevention 2017; 18 (1): 17–21. https://doi.org/10.22034/ APJCP.2017.18.1.17
  • 4. Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arquivos Brasileiros de Endocrinolologia e Metabologia 2014; 58 (2): 182–187. https:// doi.org/10.1590/0004-2730000003051
  • 5. Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obesity and Facts 2009; 2 (1): 26–35. https://doi. org/10.1159/000194971
  • 6. Insenser M, Montes-Nieto R, Murri M, Escobar-Morreale HF. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Molecular and Cellular Endocrinology 2013; 370 (1): 65-77. https://doi.org/10.1016/j.mce.2013.02.009
  • 7. Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP -1 receptor agonists. The Journal of Clinical Endocrinology and Metabolism 2020; 105 (8): e2695–e2709. https://doi.org/10.1210/clinem/ dgaa285
  • 8. Saeedi V, Nourbakhsh M, Nourbakhsh M, Haghighi L, Kamalzadeh L et al. Sestrin 2 and Beclin 1 levels in polycystic ovary syndrome. Journal of Clinical Laboratory Analysis 2021; 35 (9): e23957. https://doi.org/10.1002/jcla.23957
  • 9. Victor VM, Rocha M, Bañuls C, Alvarez A, de Pablo C et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. Journal of Clinical Endocrinology and Metabolism 2011; 96 (10): 3115-3122. https://doi.org/10.1210/ jc.2011-0651
  • 10. Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. The International Journal of Biochemistry & Cell Biology 2010; 42 (10): 1634–1650. https:// doi.org/10.1016/j.biocel.2010.06.001
  • 11. Sun Y, Li S, Liu H, Bai H, Hu K et al. Oxidative stress promotes hyperandrogenism by reducing sex hormone- binding globulin in polycystic ovary syndrome. Fertility and Sterility 2021; 116 (6): 1641-1650. https://doi.org/10.1016/j. fertnstert.2021.07.1203
  • 12. Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Human Reproduction Update 2013; 19 (3): 268-288. https://doi.org/10.1093/humupd/dms059
  • 13. Ishihara M, Urushido M, Hamada K, Matsumoto T, Shimamura Y et al. Sestrin-2 and BNIP3 regulate autophagy and mitophagy in renal tubular cells in acute kidney injury. American Journal of Physiology. Renal Physiology 2013; 305 (4): F495–F509. https://doi.org/10.1152/ ajprenal.00642.2012
  • 14. Yi L, Li F, Yong Y, Jianting D, Liting Z et al. Upregulation of sestrin-2 expression protects against endothelial toxicity of angiotensin II. Cell Biology and Toxicology 2014; 30 (3): 147– 156. https://doi.org/10.1007/s10565-014-9276-3
  • 15. Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL et al. Maintenance of metabolic homeostasis by Sestrin 2 and Sestrin 3. Cell Metabolism 2012; 16 (3): 311-321. https://doi. org/10.1016/j.cmet.2012.08.004
  • 16. Bestel A, Elmas B, Günkaya OS, Bestel M, Bahat PY. Could sestrin protein in serum be a new marker of oxidative stress in patients with polycystic ovary syndrome? Gynecological Endocrinology 2022; 38 (12):1109-1113. https://doi.org/10.108 0/09513590.2022.2163234
  • 17. Nourbakhsh M, Sharifi R, Ghorbanhosseini SS, Javad A, Ahmadpour F et al. Evaluation of plasma TRB3 and sestrin 2 levels in obese and normal-weight children. Childhood Obesity 2017; 13 (5): 409-414. https://doi.org/10.1089/chi.2017.0082
  • 18. Du K, Ding J. Insulin regulates TRB3 and other stress-responsive gene expression through induction of C/EBPβ. Molecular Endocrinology 2009; 23 (4): 475-485. https://doi.org/10.1210/ me.2008-0284
  • 19. Zhang X, Fu L, Zhang Q, Yan L, Ma Y et al. Association of TRB3 Q84R polymorphism with polycystic ovary syndrome in Chinese women. Reproductive Biology and Endocrinology: RB&E 2011; 14(9):46. https://doi.org/10.1186/1477-7827-9-46
  • 20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004; 81 (1): 19-25. https://doi. org/10.1016/j.fertnstert.2003.10.004
  • 21. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. The Journal of Clinical Endocrinology and Metabolism 1961; 21: 1440–1447. https://doi.org/10.1210/jcem- 21-11-1440
  • 22. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrine Reviews 1985; 6 (1): 45-86. https:// doi.org/10.1210/edrv-6-1-45
  • 23. Wang M, Xu Y, Liu J, Ye J, Yuan W et al. Recent insights into the biological functions of sestrins in health and disease. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 2017; 43 (5): 1731-1741. https://doi. org/10.1159/000484060
  • 24. Kim HJ, Joe Y, Kim S-K, Park SU, Park J et al. Carbon monoxide protects against hepatic steatosis in mice by inducing sestrin-2 via the PERK-eIF2α-ATF4 pathway. Free Radical Biology & Medicine 2017; 110: 81-91. https://doi.org/10.1016/j. freeradbiomed.2017.05.026
  • 25. Heidler J, Fysikopoulos A, Wempe F, Seimetz M, Bangsow T et al. Sestrin-2, a repressor of PDGFRβ signalling, promotes cigarette-smoke-induced pulmonary emphysema in mice and is upregulated in individuals with COPD. Disease Models & Mechanisms 2013; 6 (6): 1378-1387. https://doi.org/10.1242/ dmm.013482
  • 26. Morrison A, Chen L, Wang J, Zhang M, Yang H et al. Sestrin 2 promotes LKB1-mediated AMPK activation in the ischemic heart. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2015; 29 (2): 408-417. https://doi.org/10.1096/fj.14-258814
  • 27. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism 2006; 91 (1): 48-53. https://doi. org/10.1210/jc.2005-1329
  • 28. Li D, You Y, Bi FF, Zhang TN, Jiao J et al. Autophagy is activated in the ovarian tissue of polycystic ovary syndrome. Reproduction 2018; 155 (1): 85-92. https://doi.org/10.1530/REP-17-0499
  • 29. Kim H, An S, Ro SH, Teixeira F, Park GJ et al. Janus-faced Sestrin2 controls ROS and mTOR signalling through two separate functional domains. Nature Communications 2015; 27 (6): 10025. https://doi.org/10.1038/ncomms10025
  • 30. Mohammadi M. Oxidative stress and polycystic ovary syndrome: A brief review. International Journal of Preventive Medicine 2019; 17 (10): 86. https://doi.org/10.4103/ijpvm.IJPVM_576_17
  • 31. Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metabolism 2012; 16 (3): 311-321. https://doi.org/10.1016/j. cmet.2012.08.004
  • 32. Fatima MT, Hasan M, Abdelsalam SS, Sivaraman SK, El-Gamal H et al. Sestrin2 suppression aggravates oxidative stress and apoptosis in endothelial cells subjected to pharmacologically induced endoplasmic reticulum stress. European Journal of Pharmacology 2021; 907: 174247. https://doi.org/10.1016/j. ejphar.2021.174247
  • 33. Kishimoto Y, Kondo K, Momiyama Y. The protective role of Sestrin2 in atherosclerotic and cardiac diseases. International Journal of Molecular Sciences 2021; 22 (3): 1200. https://doi. org/10.3390/ijms22031200
  • 34. Xu X, Song X, Xu X, Zheng Y, Xu L et al. Inhibition of sestrin 1 alleviates polycystic ovary syndrome by decreasing autophagy. Aging 2021; 13 (8): 11774-11785. https://doi.org/10.18632/ aging.202872
  • 35. Dong XC. The potential of sestrins as therapeutic targets for diabetes. Expert Opinion on Therapeutic Targets 2015; 19 (8): 1011-1015. https://doi.org/10.1517/14728222.2015.1044976
  • 36. Cordani M, Sánchez-Álvarez M, Strippoli R, Bazhin AV, Donadelli M. Sestrins at the interface of ROS control and autophagy regulation in health and disease. Oxidative Medicine and Cellular Longevity 2019; 7: 1283075. https://doi.org/10.1155/2019/1283075
  • 37. Guo Z, Yu Q. Role of mTOR signaling in female reproduction. Frontiers in Endocrinology 2019; 9 (10): 692. https://doi. org/10.3389/fendo.2019.00692
  • 38. Saeedi V, Nourbakhsh M, Nourbakhsh M, Haghighi L, Kamalzadeh L et al. Sestrin2 and Beclin1 levels in polycystic ovary syndrome. Journal of Clinical Laboratory Analysis 2021; 35 (9): e23957. https://doi.org/10.1002/jcla.23957
  • 39. Rai N, Dey S. Protective response of Sestrin under stressful conditions in aging. Ageing Research Reviews 2020; 64: 101186. https://doi.org/10.1016/j.arr.2020.101186
  • 40. El-Ashmawy HM, Ahmed AM. Association of serum Sestrin-2 level with insulin resistance, metabolic syndrome, and diabetic nephropathy in patients with type 2 diabetes. The Egyptian Journal of Internal Medicine 2019; 31 (2): 107–114. https://doi. org/10.4103/ejim.ejim_85_18
  • 41. Chung HS, Hwang HJ, Hwang SY, Kim NH, Seo JA et al. Association of serum Sestrin2 level with metabolic risk factors in newly diagnosed drug-naïve type 2 diabetes. Diabetes Research and Clinical Practice 2018; 144: 34-41. https://doi.org/10.1016/j. diabres.2018.07.024
  • 42. Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility and Sterility 2005; 83 (1): 130-136. https:// doi.org/10.1016/j.fertnstert.2004.05.098
APA kirankaya a, Kovalak E (2023). Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. , 1697 - 1703. 10.55730/1300-0144.5738
Chicago kirankaya aysegul,Kovalak Evrim Ebru Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. (2023): 1697 - 1703. 10.55730/1300-0144.5738
MLA kirankaya aysegul,Kovalak Evrim Ebru Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. , 2023, ss.1697 - 1703. 10.55730/1300-0144.5738
AMA kirankaya a,Kovalak E Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. . 2023; 1697 - 1703. 10.55730/1300-0144.5738
Vancouver kirankaya a,Kovalak E Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. . 2023; 1697 - 1703. 10.55730/1300-0144.5738
IEEE kirankaya a,Kovalak E "Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome." , ss.1697 - 1703, 2023. 10.55730/1300-0144.5738
ISNAD kirankaya, aysegul - Kovalak, Evrim Ebru. "Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome". (2023), 1697-1703. https://doi.org/10.55730/1300-0144.5738
APA kirankaya a, Kovalak E (2023). Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. Turkish Journal of Medical Sciences, 53(6), 1697 - 1703. 10.55730/1300-0144.5738
Chicago kirankaya aysegul,Kovalak Evrim Ebru Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. Turkish Journal of Medical Sciences 53, no.6 (2023): 1697 - 1703. 10.55730/1300-0144.5738
MLA kirankaya aysegul,Kovalak Evrim Ebru Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. Turkish Journal of Medical Sciences, vol.53, no.6, 2023, ss.1697 - 1703. 10.55730/1300-0144.5738
AMA kirankaya a,Kovalak E Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. Turkish Journal of Medical Sciences. 2023; 53(6): 1697 - 1703. 10.55730/1300-0144.5738
Vancouver kirankaya a,Kovalak E Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome. Turkish Journal of Medical Sciences. 2023; 53(6): 1697 - 1703. 10.55730/1300-0144.5738
IEEE kirankaya a,Kovalak E "Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome." Turkish Journal of Medical Sciences, 53, ss.1697 - 1703, 2023. 10.55730/1300-0144.5738
ISNAD kirankaya, aysegul - Kovalak, Evrim Ebru. "Evaluation of sestrin 2 and tribbles homolog 3 levels in obese and nonobese women with polycystic ovary syndrome". Turkish Journal of Medical Sciences 53/6 (2023), 1697-1703. https://doi.org/10.55730/1300-0144.5738